Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Standard BioTools Inc LAB

Technology Scientific & Technical Instruments
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.


NDAQ:LAB - Post by User

Standard BioTools Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(73)
•••
Post by Humaniston Feb 17, 2022 6:44pm
272 Views
Post# 34440029

FLDM EARNINGS OUT/ WITH A BEAT. DETAILS BELOW

FLDM EARNINGS OUT/ WITH A BEAT. DETAILS BELOWFldm financial results summary, follOw link for complete NR (V LONG)
 
https://forextv.com/top-news/fluidigm-announces-fourth-quarter-and-full-year-2021-financial-results/
 
Fourth Quarter 2021 Financial Results  
Total revenue was $38.3 million for the quarter ended December 31, 2021, compared with $44.6 million for the fourth quarter of 2020. Base product and service revenue (excluding COVID-19 testing revenue) increased 13.5 percent to $35.3 million, compared with $31.1 million in the same period last year.

GAAP net loss for the quarter was $9.4 million, compared with a GAAP net loss of $18.0 million for the fourth quarter of 2020.  
Non-GAAP net loss was $0.8 million for the quarter, compared with a non-GAAP net loss of $9.8 million for the fourth quarter of 2020.  
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities